1. Scrip
  2. >>Business
  3. >>Deals

Merck KGaA Cancer Deal-Making Spree Continues With PDS Tie-Up

Licenses Promising Candidate For $5m Upfront

 
• By Kevin Grogan

PDS is getting rights to Merck's M9241, a tumor-targeting interleukin-12 fusion compound which is a key component, together with its own investigational HPV16-targeted immunotherapy, in a triple combination being studied to treat advanced HPV-positive cancers.

Merck KGaA Darmstadt
• Source: Merck KGaA

Merck KGaA has continued its run of dealmaking in the oncology field by licensing out its tumor-targeting interleukin-12 fusion protein M924 to PDS Biotechnology Corporation.

The German group will receive $5m upfront, up to $11m in development and regulatory payments and $105m in commercial milestones,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By Joseph Haas

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.